The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued products.

GlobalData tracks 173 drugs in development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by 155 companies/universities/institutes. The top development phase for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections is preclinical with 98 drugs in that stage. The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline has 115 drugs in development by companies and 58 by universities/ institutes. Some of the companies in the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline products market are: Wockhardt, Acticule Life Sciences and Q2 Pharma.

The key targets in the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline products market include Bacterial Cell Membrane, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9), and Bacterial Cell Wall.

The key mechanisms of action in the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline product include Bacterial Cell Membrane Disruptor with seven drugs in Phase II. The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline products include 11 routes of administration with the top ROA being Intravenous and 18 key molecule types in the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline products market including Small Molecule, and Synthetic Peptide.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections overview

Methicillin-resistant Staphylococcus aureus (MRSA) infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections; others are hospital-aquired (HA-MRSA). Risk factors for MRSA infection are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

For a complete picture of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.